NYSE · Healthcare · Medical Devices
Edwards Lifesciences Corporation (EW)
As of Sep 25, 4:00 PM ET, Edwards Lifesciences (EW) last traded at $86.29, up 0.65% on the day. Its TickerHum research score is 63/100 (above average). It reported revenue of $6.51B for the twelve months ending 2026-06-30, up 14.6% year over year, with a 22.3% operating margin.
Ratings
- Valuation: 45/100 — Strongest input: price / sales (ttm) 7.6x. Weakest: price / earnings (ttm) 50.2x.
- Growth: 31/100 — Strongest input: revenue growth (ttm, yoy) +14.6 %. Weakest: diluted eps growth (ttm, yoy) -75.3 %.
- Profitability: 69/100 — Strongest input: gross margin 77.8 %. Weakest: return on equity 9.5 %.
- Financial health: 99/100 — Strongest input: current ratio 4.52. Weakest: long-term debt / equity 0.06.
- Momentum: 48/100 — Strongest input: price vs 200-day average +1.4 %. Weakest: 3-month return -4.9 %.
- Attention: 58/100 — Strongest input: headlines in the last 7 days 21. Weakest: volume vs 3-month average 0.9x.
- Risk: 85/100 — Strongest input: max drawdown (1y) -13.2 %. Weakest: annualised volatility (1y) 25.2 %.
- Data confidence: 92/100 — Strongest input: inputs available 100 %. Weakest: quote age (hours) 46 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $6.51B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | 14.6% | TTM ending 2026-06-30 · 10-Q |
| Net income | $1B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | $1.72 | TTM ending 2026-06-30 · 10-Q |
| Gross margin | 77.8% | TTM ending 2026-06-30 · 10-Q |
| Operating margin | 22.3% | TTM ending 2026-06-30 · 10-Q |
| Net margin | 15.4% | TTM ending 2026-06-30 · 10-Q |
| Free cash flow | $1.43B | TTM ending 2026-06-30 · 10-Q |
| Cash | $2.91B | as of 2026-06-30 · 10-Q |
| Long-term debt | $598.7M | as of 2026-06-30 · 10-Q |
| Debt / equity | 0.06 | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0001099800).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.